KAI Pharmaceuticals
South San Francisco, California, United States
About KAI Pharmaceuticals
KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 10,001+
- Total funding: $52.0M
- Funding stage: M&A
- Last round: Series B (May 2006)
- Website: kaipharmaceuticals.com
- Phone: 650-244-1100
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kai-pharmaceuticals-2454049 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.